Focused Drug Development News Today

The American College of Cardiology’s Cardiac Oncology Conference, “Advancing the Cardiovascular Care of the Oncology Patient,” will be held at the Heart House in Washington, D.C., Feb. 9-11, 2024. The event is offered as an interdisciplinary and interspecialty course with a robust program providing clinicians and researchers with the tools needed to improve the cardiovascular (CV) health of cancer patients in everyday practice.

Submitting Patient-Reported Outcome Data in Cancer Clinical Trials

Company Logo MindMed Investor Presentation August 2023 Disclaimer This presentation has been prepared by Mind Medicine Inc. solely for informational purposes. None of... -Today at 05:35 pm- MarketScreener

Toronto, ON (PRWEB) June 02, 2023 -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical

AUSTIN, Texas, May 22, 2023 -- Lumos Pharma, Inc. , a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency through Phase 2 clinical... | May 22, 2023

Toronto, ON (PRWEB) April 03, 2023 -- The new FDA Patient Focused Drug Development (PFDD) Guidance Series and the Core Patient-Reported Outcomes Measures

With the greater emphasis on patient-centricity, patients are valued as an active participant in their own care. There is an increased emphasis on...

/PRNewswire/ -- GC Biopharma (006280.KS) and Speragen today announced that a joint Externally Led - Patient-Focused Drug Development (EL-PFDD) meeting hosted...

/PRNewswire/ -- inVibe Labs (http://www.invibe.co), a pioneer in the field of voice technology for market research, and recently included on the Inc. 5000 list...

To print this article, all you need is to be registered or login on Mondaq.com. Sunday, February 28, 2021, was Rare Disease Day. With so much focus on COVID-19 throughout 2020, its important to recognize the continued work done in rare disease drug development by sponsors and FDA throughout 2020. In addition, a number of policies implemented in response to COVID-19 are expected to have a positive impact on rare disease drug development going forward. Yet, the lasting nat...